StoxOnesource Specialty Pharma vs NATCO Pharma: share price & financials comparison
NSE: ONESOURCE vs NATCOPHARM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs NATCO Pharma at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,463 Cr, against ₹14,507 Cr for NATCO Pharma (NATCOPHARM). Over the past year NATCO Pharma has returned -1.1%, compared with -12.2% for Onesource Specialty Pharma. NATCO Pharma earns a higher return on equity (8.5% vs -0.0%). Onesource Specialty Pharma comes out ahead on growth, momentum and technicals. NATCO Pharma comes out ahead on size, valuation, profitability and financial health. Across the scored metrics below, Onesource Specialty Pharma leads on 5 and NATCO Pharma on 7. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and NATCO Pharma scores 5/10.
| Metric | Onesource Specialty Pharma | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹18,463 Cr | ₹14,507 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | — | 17.5 |
| P/B | 3.12 | 1.49 |
| Dividend yield | — | 0.62% |
| Profitability | ||
| Return on equity | 0.0% | 8.5% |
| Net profit margin | -0.1% | 26.8% |
| Operating margin | 23.5% | 23.7% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | -29.0% |
| Net profit growth (YoY) | +687.0% | -60.9% |
| Revenue CAGR (multi-year) | — | +14.7% |
| Financial health | ||
| Debt to equity | 0.25 | 0.11 |
| Momentum | ||
| 1-month return | +10.3% | +2.7% |
| 1-year return | -12.2% | -1.1% |
| 3-year CAGR | — | +0.7% |
| 5-year CAGR | — | -0.9% |
| 10-year CAGR | — | +2.2% |
| Distance from 52W high | -13.8% | -32.8% |
| Technicals | ||
| RSI (14) | 82 | 65 |
| Price vs 200-day avg | +4.0% | -12.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 4/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or NATCO Pharma?
Onesource Specialty Pharma has a market cap of ₹18,463 Cr and NATCO Pharma has a market cap of ₹14,507 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or NATCO Pharma?
NATCO Pharma did better: Onesource Specialty Pharma returned -12.2% and NATCO Pharma returned -1.1% over one year.
What is the difference between Onesource Specialty Pharma and NATCO Pharma?
Both are NSE-listed companies in Healthcare. Onesource Specialty Pharma is about 1.3 times the size of NATCO Pharma by market cap. In the latest financial year Onesource Specialty Pharma reported revenue of ₹1,422 Cr and NATCO Pharma ₹4,078 Cr. Operating margin is 23.5% for Onesource Specialty Pharma and 23.7% for NATCO Pharma. Debt to equity is 0.25 for Onesource Specialty Pharma and 0.11 for NATCO Pharma.
Which is better, Onesource Specialty Pharma or NATCO Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Onesource Specialty Pharma leads on 5 and NATCO Pharma on 7. Onesource Specialty Pharma is ahead on growth, momentum and technicals. NATCO Pharma is ahead on size, valuation, profitability and financial health. On StoxGud's rules-based checklist Onesource Specialty Pharma scores 4/10 and NATCO Pharma scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.